Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
ATLANTA, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced that it has activated enrollment for its pivotal FemBloc trial at another academic site, University of Utah Hospital in Salt Lake City, Utah. The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control (the “FINALE” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®. The FDA-approved, multi-center trial is designed to help women seeking permanent birth control, for whom elective surgery currently remains the only option.
- The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control (the “FINALE” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®.
- The FDA-approved, multi-center trial is designed to help women seeking permanent birth control, for whom elective surgery currently remains the only option.
- Gawron’s consistent involvement demonstrates support for FemBloc and the importance that it may hold in providing optionality to women seeking additional and improved birth control options."
- An in-office option like FemBloc has the opportunity to change how we deliver care to women when they no longer wish to be at risk of pregnancy but no longer want exposure to hormones or implants or surgery.”